Trifluoromethyldeschloroketamine
![]()  | |
| Clinical data | |
|---|---|
| ATC code | 
  | 
| Legal status | |
| Legal status | 
  | 
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C14H16F3NO | 
| Molar mass | 271.283 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
Trifluoromethyldeschloroketamine (TFMDCK) is a designer drug from the arylcyclohexylamine family, which is presumed to have similar properties to ketamine, a dissociative anesthetic drug with hallucinogenic and sedative effects. It has been sold over the internet since around 2016, though genuine samples appear to be rare.[1] The o-trifluoromethyl analogue of hydroxynorketamine has also been researched as an antidepressant.[2]
See also
- Bromoketamine
 - Deschloroketamine
 - Methoxyketamine
 - Methoxmetamine
 
References
- ↑ Wallach J, Brandt SD (2018). "1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 305–352. doi:10.1007/164_2018_148. ISBN 978-3-030-10560-0. PMID 30196446.
 - ↑ 种长效化合物的制备方法. Chinese patent CN 110540510A, 18 June 2019
 
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
